Y-mAbs和Nobelpharma签署DANYELZA在日本的许可和分销协议

2024-11-04 21:49

Y-mAbs Therapeutics (NASDAQ:YMAB)and Nobelpharma on Monday announced that they have signed an exclusive license and distribution agreement for the development and commercialization of DANYELZA in Japan.
As per the agreement, Nobelpharma will carry out development work and submit DANYELZA for approval by Japanese regulatory authorities. If approved, Nobelpharma will market, sell, and distribute DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and potentially relapsed osteosarcoma in Japan.
Pursuant to the agreement, Y-mAbs will receive an upfront payment of $2M from Nobelpharma in connection with entering into the agreement. Y-mAbs is also entitled to receive up to $31M in product and commercial milestone payments in addition to profit sharing on commercial sales on DANYELZA.
YMAB +1.08% premarket to $14.9.
Source: Press Release

More on Y-mAbs Therapeutics